| Coverage of nonpharmacologic treatments for low back pain among US public and private insurers J Heyward, CM Jones, WM Compton, DH Lin, JL Losby, IB Murimi, ... JAMA Network Open 1 (6), e183044-e183044, 2018 | 146 | 2018 |
| Attributes common to programs that successfully treat high-need, high-cost individuals GF Anderson, J Ballreich, S Bleich, C Boyd, E DuGoff, B Leff, C Salzburg, ... Am J Manag Care 21 (11), e597-e600, 2015 | 89 | 2015 |
| Equitable access to care—how the United States ranks internationally K Davis, J Ballreich New England Journal of Medicine 371 (17), 1567-1570, 2014 | 74 | 2014 |
| Economic value of vaccines to address the COVID-19 pandemic: a US cost-effectiveness and budget impact analysis WV Padula, S Malaviya, NM Reid, BG Cohen, F Chingcuanco, J Ballreich, ... Journal of medical economics 24 (1), 1060-1069, 2021 | 70 | 2021 |
| Prescription drug coverage for treatment of low back pain among US Medicaid, Medicare Advantage, and commercial insurers DH Lin, CM Jones, WM Compton, J Heyward, JL Losby, IB Murimi, ... JAMA network open 1 (2), e180235-e180235, 2018 | 65 | 2018 |
| Allocation of National Institutes of Health funding by disease category in 2008 and 2019 JM Ballreich, CP Gross, NR Powe, GF Anderson JAMA Network Open 4 (1), e2034890-e2034890, 2021 | 54 | 2021 |
| Cost‐effectiveness analysis comparing dupilumab and aspirin desensitization therapy for chronic rhinosinusitis with nasal polyposis in aspirin‐exacerbated respiratory disease M Yong, YQ Wu, J Howlett, J Ballreich, E Walgama, A Thamboo International Forum of Allergy & Rhinology 11 (12), 1626-1636, 2021 | 45 | 2021 |
| Modeling mitigation strategies to reduce opioid-related morbidity and mortality in the US J Ballreich, O Mansour, E Hu, F Chingcuanco, HA Pollack, DW Dowdy, ... JAMA network open 3 (11), e2023677-e2023677, 2020 | 44 | 2020 |
| Bridging the silos of service delivery for high-need, high-cost individuals M Sherry, JL Wolff, J Ballreich, E DuGoff, K Davis, G Anderson Population health management 19 (6), 421-428, 2016 | 39 | 2016 |
| Cost-effectiveness of school hearing screening programs: a scoping review M Yong, J Liang, J Ballreich, J Lea, BD Westerberg, SD Emmett Otolaryngology–Head and Neck Surgery 162 (6), 826-838, 2020 | 35 | 2020 |
| Financing and delivering pre-exposure prophylaxis (PrEP) to end the HIV epidemic A Killelea, J Johnson, DT Dangerfield II, C Beyrer, M McGough, J McIntyre, ... Journal of Law, Medicine & Ethics 50 (S1), 8-23, 2022 | 33 | 2022 |
| Mobile health school screening and telemedicine referral to improve access to specialty care in rural Alaska: a cluster-randomised controlled trial SD Emmett, A Platt, EL Turner, JJ Gallo, AB Labrique, SM Inglis, ... The Lancet Global Health 10 (7), e1023-e1033, 2022 | 29 | 2022 |
| Does fracture care make money for the hospital? An analysis of hospital revenues and costs for treatment of common fractures CP Kleweno, RV O'Toole, J Ballreich, AN Pollak Journal of orthopaedic trauma 29 (7), e219-e224, 2015 | 27 | 2015 |
| Factors associated with high short-acting β2-agonist use in urban children with asthma AM Butz, J Ogborn, S Mudd, J Ballreich, M Tsoukleris, J Kub, M Bellin, ... Annals of Allergy, Asthma & Immunology 114 (5), 385-392, 2015 | 25 | 2015 |
| Medicare spending on drugs with accelerated approval J Ballreich, M Socal, CL Bennett, MW Schoen, A Trujillo, A Xuan, ... Annals of internal medicine 175 (7), 938-944, 2022 | 14 | 2022 |
| Reducing branded prescription drug prices: A review of policy options GC Alexander, J Ballreich, MP Socal, T Karmarkar, A Trujillo, J Greene, ... Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy 37 (11 …, 2017 | 14 | 2017 |
| Effect of reductions in opioid prescribing on opioid use disorder and fatal overdose in the United States: a dynamic Markov model GC Alexander, J Ballreich, O Mansour, DW Dowdy Addiction 117 (4), 969-976, 2022 | 13 | 2022 |
| Cost-effectiveness of systemic treatments for metastatic castration-sensitive prostate cancer: an economic evaluation based on network meta-analysis L Wang, H Hong, GC Alexander, OW Brawley, CJ Paller, J Ballreich Value in Health 25 (5), 796-802, 2022 | 10 | 2022 |
| Association between US Pharmacopeia (USP) monograph standards, generic entry and prescription drug costs IB Murimi-Worstell, JM Ballreich, MJ Seamans, GC Alexander Plos one 14 (11), e0225109, 2019 | 10 | 2019 |
| Branded prescription drug spending: a framework to evaluate policy options J Ballreich, GC Alexander, M Socal, T Karmarkar, G Anderson Journal of Pharmaceutical Policy and Practice 10 (1), 31, 2017 | 10 | 2017 |
G. Caleb AlexanderJohns Hopkins Center for Drug Safety and EffectivenessEmail verificata su jhsph.edu